Abstract
Over the past 20 years Organon have been involved in developing a new series of progestogens characterized by the absence of an oxygen at position 3 of the steroid skeleton. Following lynestrenol, the most promising compound in early trials was desogestrel, a 13-ethyl-11-methylene-3-desoxy compound, which is a more specific progestogen than both norethisterone and levonorgestrel1. Receptor binding studies have demonstrated a lower affinity of the main metabolite of desogestrel for androgen receptors than levonorgestrel1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bergink, E. W., Hamburger, A. D., De Jager, E. and van der Vies, J. (1981). Binding of a contraceptive progestogen Org 2969 and its metabolites to receptor proteins and human sex hormone binding globulin. J. Steroid Biochem., 14, 175
Weijers, M. J. (1982). Clinical trial of an oral contraceptive containing 150µg desogestrel and 30µg ethinyloestradiol. Clin. Ther., 4, 359
Samsioe, G. (1982). Comparative effects of the oral contraceptive combinations 0.0150 mg desogestrel + 0.030 mg ethinyloestradiol and 0.150 mg levonorgestrel + 0.030 mg ethinyloestradiol on lipid and lipoprotein metabolism in healthy female volunteers. Contraception, 25, 487
Bergink, E. W., Borglin, N. E., Klottrup, P. and Liukko, P. (1982). Effects of desogestrel and levonorgestrel in low-dose oestrogen oral contraceptives on serum lipoproteins. Contraception, 25, 477
Gordon, T., Castelli, W. P. and Njortland, M. (1977). HDL as a protective factor against CHD — The Framingham study. Am. J. Med., 62, 707
Bergink, E. W., Holma, P. and Pyorala, T. (1981). Effects of oral contraceptive combinations containing levonorgestrel or desogestrel on serum proteins and androgen binding. Scand. J. Clin. Lab. Invest., 41, 663
Burstein, M., Scholnik, H. R. and Morfin, R. (1978). Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid. Res., 11, 583
Winer, B. J. (1971). Statistical Principles in Experimental Design. ( New York: McGraw Hill )
Borglin, N. E., Christensen, O. J. E., Culberg, G. et al. (1982). Scandinavian trial of an oral contraceptive containing 0.150 mg desogestrel and 0.03 mg ethinyloestradiol. Acta Obstet. Gynecol. Scand., 111, 39
Culberg, G., Samsioe, G., Andersen, R. F., et al. (1982). Two oral contraceptives, efficacy, serum proteins and lipid metabolism. Contraception, 26, 229
Bradley, D. D., Wingerd, J., Petitti, D. B., et al. (1978). Serum high density lipoproteins cholesterol in women using oral contraceptives, estrogens and progestins. N. Engl. J. Med., 299, 17
Kay, C. R. (1980). The happiness pill? J. R. Coll. Gen. Pract., 30, 8
el Makzangy, M. N., Wynn, V. and Lawrence, D. M. (1979). Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin. Endocrinol., 10, 39
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer Science+Business Media New York
About this chapter
Cite this chapter
Newton, J.R. (1984). Studies with desogestrel for fertility regulation. In: Harrison, R.F., Thompson, W., Bonnar, J. (eds) Trends in Oral Contraception. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-3600-8_7
Download citation
DOI: https://doi.org/10.1007/978-94-017-3600-8_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5802-7
Online ISBN: 978-94-017-3600-8
eBook Packages: Springer Book Archive